1-4 of 4
Andrew J Davies, MRCP PhD
Close
Sort by
Journal Articles

Defining Immune Response Signatures in DLBCL As Potential Predictive Biomarkers for Outcome to Immunotherapy

Matthew A Care, PhD, Stephen M Thirdborough, PhD, Andrew J Davies, MRCP PhD, Peter W.M. Johnson, FRCP, Andrew Jack, PhD MB, Sharon Barrans, PhD, David R Westhead, PhD, Mark S Cragg, PhD, Reuben M Tooze, PhD FRCP, Stephen A Beers, PhD
Journal: Blood
Blood (2015) 126 (23): 2663.
https://doi.org/10.1182/blood.V126.23.2663.2663
Published: 2015
Journal Articles

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Andrew J Davies, MRCP PhD, Josh Caddy, Tom Maishman, Sharon Barrans, PhD, Christoph Mamot, MD, Matthew Care, PhD, Christopher Pocock, Louise Stanton, PhD, Debbie Hamid, Keith Pugh, PhD, Andrew McMillan, PhD, Paul Fields, MDPhD, Anton Kruger, Andrew Jack, PhD MB, Peter W. M. Johnson, FRCP
Journal: Blood
Blood (2015) 126 (23): 812.
https://doi.org/10.1182/blood.V126.23.812.812
Published: 2015
Journal Articles

Patients With DLBCL Commonly Have B-Cell Lymphopenia and Circulating Clonal B-Cell Populations With a Phenotype Concordant With The Underlying Tumour

Ruth M de Tute, MSc, Sharon Barrans, PhD, Andy C. Rawstron, PhD, Peter W.M. Johnson, MD, FRCP, Andrew J Davies, MRCP, PhD, Andrew Jack, PhD
Journal: Blood
Blood (2013) 122 (21): 3013.
https://doi.org/10.1182/blood.V122.21.3013.3013
Published: 2013
Journal Articles

Defects In Lymphocyte Subsets and Serological Memory Persist a Median of 10 Years After High Dose Therapy and Autologous Progenitor Cell Rescue for Malignant Lymphoma

Harry F Dean, BSc, Angelica Cazaly, PhD, Carol Hurlock, Anthony P Williams, MRCP, FRCPath, PhD, Peter W Johnson, MD, FRCP, Andrew J Davies, MRCP, PhD
Journal: Blood
Blood (2010) 116 (21): 1265.
https://doi.org/10.1182/blood.V116.21.1265.1265
Published: 2010